Publications
371
Citations
10,276
Est. group size
~23
Recurring co-author estimate
Active years
20
Publishing since 2006
Yvonne A. Efebera's research centers on multiple myeloma and related blood cancers, focusing on stem cell transplantation, cellular and immune therapies (such as CAR-T and bispecific antibodies), and new drug combinations. Much of the work involves large multicenter clinical trials evaluating treatment outcomes, quality of life, and disparities in access to care among patients with multiple myeloma and other blood disorders. The research combines clinical trial analysis with laboratory studies of immune responses and cancer vaccines.
Publication output has fluctuated but generally increased over the last decade, rising from about 18 papers per year in 2017 to a peak of 44 in 2023, with continued high output in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
Blood Advances · 2025
- Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review
Blood · 2025
- Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
Journal of Clinical Oncology · 2025
- Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
Leukemia · 2025
- Curcumin and resveratrol sensitizes TP53 mutant acute myeloid leukemia (AML) cell lines to venetoclax-induced apoptosis
Blood · 2025
- Tolerability of Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series
Transplantation and Cellular Therapy · 2025
- Neoantigen Expression and Expansion of Cytotoxic T Cell Clonotypes in Multiple Myeloma Patients Randomized to Post-Transplant Treatment with a Personalized Cancer Vaccine Under the BM CTN 1401 Multicenter Trial.
Transplantation and Cellular Therapy · 2025
- Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies
Patient Preference and Adherence · 2025
- Abstract 7128: Neoantigen expression and expansion of cytotoxic T cell clonotypes in multiple myeloma patients receiving a personalized cancer vaccine post-transplant: Insights from the BM CTN 1401 multicenter trial
Cancer Research · 2025
- Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies [Corrigendum]
Patient Preference and Adherence · 2025
- Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series
Clinical Lymphoma Myeloma & Leukemia · 2025
- Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: A Center for International Blood & Marrow Transplantation Research (CIBMTR) Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- Uncovering Shared Cancer-Restricted Cryptic Antigens as T Cell Targets in Multiple Myeloma Patients Treated with Dendritic Cell/Myeloma Fusion Vaccine
Clinical Lymphoma Myeloma & Leukemia · 2025
- Exploratory Analyses of Progression-Free Survival (PFS) with Lenalidomide-Bortezomib-Dexamethasone (RVd) Alone/RVd+ASCT by Duffy genotype in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma & Leukemia · 2025
- Safety and Efficacy of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- Blood×70
- Biology of Blood and Marrow Transplantation×27
- Transplantation and Cellular Therapy×17
- Clinical Lymphoma Myeloma & Leukemia×16
- Journal of Clinical Oncology×13
- Abdullah Khan
Medicine · The Ohio State University
- Don Benson
Medicine · The Ohio State University
- Don M. Benson
Medicine · The Ohio State University
- Naresh Bumma
Medicine · The Ohio State University
- Rafat Abonour
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile